FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W40915523> ?p ?o ?g. }

• W40915523 endingPage "18" @default.
• W40915523 startingPage "1" @default.
• W40915523 abstract "In 2011, the Agency for Health Care Research and Quality (AHRQ) published a systematic review on the comparative effectiveness of disease-modifying anti-rheumatic drugs (DMARDs) used to treat adults with rheumatoid arthritis (RA). The publication was an update to a 2007 report. A total of 258 published articles were used in the AHRQ review to compare the effectiveness of corticosteroids, and oral and biologic DMARDs in the treatment of RA. Head-to-head studies and prospective cohort trials were used to compare one drug to another in determining efficacy and effectiveness. AHRQ compiled this report in an attempt to summarize and integrate the available data for clinicians to make evidence based practice decisions for their patients since there is limited consensus among the medical community regarding the comparative effectiveness of drugs used to treat RA. The report reveals there is still much research to be done concerning the side effects of these agents and their influence in different patient subgroups.To: (a) utilize review findings to make diagnostic and treatment management decisions in clinical practice, (b) inform clinicians on the findings from the updated AHRQ's 2011 comparative effectiveness review on drug therapy for RA in adults, and (c) identify shortcomings in the current research and future directions revealed by the report.Rheumatoid arthritis is a major public health burden. The 2011 updated AHRQ report includes several new medications approved by the FDA since 2007. The review includes 31 head-to-head randomized clinical trials (RCTs), 1 head-to-head nonrandomized controlled trial, 44 placebo controlled trials, 28 meta-analyses or systematic reviews, and 107 observational studies. Most of the studies used for the comparative analysis are of fair quality with an insufficient to moderate strength of evidence assigned to the findings (Table 1). A mixed treatment comparisons (MTC)meta-analysis from the AHRQ report found that the biologic etanercept has a higher probability of improvement in disease activity compared with other biologic DMARDs, but the MTC findings have a low strength of evidence and caution is recommended in the interpretation of this weak evidence. For patients with early RA, limited evidence precludes conclusions about the superiority of one combination therapy versus another. The data are also inconclusive for comparisons of therapeutic similarity among oral DMARDs including the limitation created by differences inmethotrexate (MTX) dosing across trials. Extensive clinical experience over the years support the preferred use of MTX in most patients versus other oral DMARDs as well as its use in multidrug regimens, whereas there is little data on the use of oral DMARDs in combination with biologic agents. The review does not support a specific biologic DMARD over another due to the lack of head-to-head trials comparing these agents using validated RA outcome measures. The data show that the majority of biologics have approximately the same efficacy except for anakinra, which was found to be less effective. The biologic and oral DMARDs are similar in overall tolerability, but several studies suggest that adverse events are more common with biologic DMARDs versus oral DMARDs. Based on limited evidence, the oral DMARDs do not appear to have an increased risk of severe adverse events including cardiovascular events and cancer. Although most studies also found no increased risk of cardiovascular events or cancer with the biologic DMARDs, cohort studies show an increased risk of heart failure with adalimumab, etanercept, and infliximab compared with oral DMARDs. The updated AHRQ review synthesizes the current literature on therapies used for the treatment of RA in adults. The investigators are also able to identify pertinent research gaps in the literature that can be addressed with future research." @default.
• W40915523 created "2016-06-24" @default.
• W40915523 creator A5016365192 @default.
• W40915523 creator A5032328215 @default.
• W40915523 date "2012-05-01" @default.
• W40915523 modified "2023-10-13" @default.
• W40915523 title "Summary of AHRQ’s Comparative Effectiveness Review of Drug Therapy for Rheumatoid Arthritis (RA) in Adults – An Update" @default.
• W40915523 cites W1550247426 @default.
• W40915523 cites W159282500 @default.
• W40915523 cites W1820622478 @default.
• W40915523 cites W1833163659 @default.
• W40915523 cites W1836301141 @default.
• W40915523 cites W1849140529 @default.
• W40915523 cites W1863065049 @default.
• W40915523 cites W1874236485 @default.
• W40915523 cites W1966438794 @default.
• W40915523 cites W1966439074 @default.
• W40915523 cites W1966756501 @default.
• W40915523 cites W1970375970 @default.
• W40915523 cites W1975501001 @default.
• W40915523 cites W1977078113 @default.
• W40915523 cites W1980464290 @default.
• W40915523 cites W1980521490 @default.
• W40915523 cites W1981859794 @default.
• W40915523 cites W1982348705 @default.
• W40915523 cites W1984181327 @default.
• W40915523 cites W1985124708 @default.
• W40915523 cites W1986479542 @default.
• W40915523 cites W1987312456 @default.
• W40915523 cites W1988848155 @default.
• W40915523 cites W1991831820 @default.
• W40915523 cites W1994065448 @default.
• W40915523 cites W1996389186 @default.
• W40915523 cites W1998500500 @default.
• W40915523 cites W1999777294 @default.
• W40915523 cites W2000962647 @default.
• W40915523 cites W2001107080 @default.
• W40915523 cites W2007252822 @default.
• W40915523 cites W2010964474 @default.
• W40915523 cites W2014709373 @default.
• W40915523 cites W2015215846 @default.
• W40915523 cites W2020820317 @default.
• W40915523 cites W2024272597 @default.
• W40915523 cites W2039110250 @default.
• W40915523 cites W2039207296 @default.
• W40915523 cites W2046549669 @default.
• W40915523 cites W2046628605 @default.
• W40915523 cites W2054059257 @default.
• W40915523 cites W2054504654 @default.
• W40915523 cites W2063308573 @default.
• W40915523 cites W2067257696 @default.
• W40915523 cites W2068985697 @default.
• W40915523 cites W2069473482 @default.
• W40915523 cites W2070055998 @default.
• W40915523 cites W2070275694 @default.
• W40915523 cites W2074409941 @default.
• W40915523 cites W2075994714 @default.
• W40915523 cites W2079590652 @default.
• W40915523 cites W2080506899 @default.
• W40915523 cites W2080638211 @default.
• W40915523 cites W2084235819 @default.
• W40915523 cites W2084834960 @default.
• W40915523 cites W2084911737 @default.
• W40915523 cites W2096349837 @default.
• W40915523 cites W2097341637 @default.
• W40915523 cites W2097564087 @default.
• W40915523 cites W2097997129 @default.
• W40915523 cites W2098077764 @default.
• W40915523 cites W2099199787 @default.
• W40915523 cites W2100974168 @default.
• W40915523 cites W2107381832 @default.
• W40915523 cites W2107690729 @default.
• W40915523 cites W2108650270 @default.
• W40915523 cites W2110459269 @default.
• W40915523 cites W2111153776 @default.
• W40915523 cites W2114270885 @default.
• W40915523 cites W2114308202 @default.
• W40915523 cites W2115068422 @default.
• W40915523 cites W2115200931 @default.
• W40915523 cites W2116843833 @default.
• W40915523 cites W2117738981 @default.
• W40915523 cites W2118704147 @default.
• W40915523 cites W2118994799 @default.
• W40915523 cites W2121422664 @default.
• W40915523 cites W2127014397 @default.
• W40915523 cites W2127608887 @default.
• W40915523 cites W2129400639 @default.
• W40915523 cites W2129841863 @default.
• W40915523 cites W2129867349 @default.
• W40915523 cites W2130837495 @default.
• W40915523 cites W2131882149 @default.
• W40915523 cites W2133541603 @default.
• W40915523 cites W2133837925 @default.
• W40915523 cites W2136236607 @default.
• W40915523 cites W2136453736 @default.
• W40915523 cites W2138712728 @default.
• W40915523 cites W2140219205 @default.
• W40915523 cites W2140669143 @default.

• next